Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Part of paid clinical trials in Los Angeles, California.

Sponsor
Pfizer
Study ID
NCT01375127
Status
Completed

Conditions

  • Kidney Transplantation

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    Subjects who previously took 15 mg BID or 30 mg BID
  • Tofacitinib — DRUG
    Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID

Study Details

This is an observational study designed to collect follow-up clinical date on subjects who were treated with tofacitinib in 2 completed Phase 2 studies who either discontinued treatment prematurely or did not elect to enroll in long-term extension studies.

Key Dates

Start date
Aug 31, 2011
Status verified
Sep 2013
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012

Study Design

Enrollment
83 participants (actual)

Arms

  • Arm: Subjects from Study A3921009
  • Arm: Subjects from Study A3921030

Primary Outcome Measure

Number of Participants With Clinical Outcome of Post Transplant Lymphoproliferative Disease (PTLD) [ Time Frame: Baseline through Month 12 ]

Locations (23)

FacilityCityStateZIPSite coordinators
Pfizer Investigational SiteLos AngelesCalifornia90024-
Pfizer Investigational SiteLos AngelesCalifornia90095-
Pfizer Investigational SitePalo AltoCalifornia94304-
Pfizer Investigational SiteSan FranciscoCalifornia94115-
Pfizer Investigational SiteSan FranciscoCalifornia94143-
Pfizer Investigational SiteStanfordCalifornia94305-
Pfizer Investigational SiteAuroraColorado80045-
Pfizer Investigational SiteTampaFlorida33606-
Pfizer Investigational SiteChicagoIllinois60611-
Pfizer Investigational SiteChicagoIllinois60637-
Pfizer Investigational SiteBostonMassachusetts02215-
Pfizer Investigational SiteSpringfiledMassachusetts01107-
Pfizer Investigational SiteAnn ArborMichigan48109-
Pfizer Investigational SiteDetroitMichigan48202-
Pfizer Investigational SiteSt LouisMissouri63110-
Pfizer Investigational SiteLivingstonNew Jersey07039-
Pfizer Investigational SiteNew YorkNew York10029-
Pfizer Investigational SiteValhallaNew York10595-
Pfizer Investigational SiteChapel HillNorth Carolina27599-7211-
Pfizer Investigational SiteDallasTexas75204-
Pfizer Investigational SiteDallasTexas75246-
Pfizer Investigational SiteFort WorthTexas76104-
Pfizer Investigational SiteRichmondVirginia23298-

Find similar trials in Los Angeles, CA

Related Studies